Genomes and Genes
Affiliation: University of California
- Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer diseasePaul S Aisen
University of California, San Diego, California 92093, USA
Cold Spring Harb Perspect Med 2:a006395. 2012..We also review putative therapies that aim to slow disease progression by mechanisms not directly related to amyloid or tau...
- Clinical trial methodologies for disease-modifying therapeutic approachesPaul S Aisen
Department of Neurosciences, University of California San Diego, La Jolla, CA 92093, USA
Neurobiol Aging 32:S64-6. 2011..Data suggest that neuroimaging biomarkers will be useful as endpoints for trials in very early, even asymptomatic disease, though further work is necessary to establish validity for regulatory purposes...
- Recent developments in Alzheimer's disease therapeuticsMichael S Rafii
Department of Neurosciences, University of California San Diego, Gilman Drive M C 0949, La Jolla, CA 92093, USA
BMC Med 7:7. 2009..In this review, we briefly discuss the current status of Alzheimer's disease therapies under study, as well the scientific context in which they have been developed...
- Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's diseaseRandall J Bateman
Department of Neurology, Washington University School of Medicine, 660 S, Euclid, Campus Box 8111, St Louis, MO 63110, USA
Alzheimers Res Ther 3:1. 2011..Clinical trials in autosomal-dominant Alzheimer's disease may test the amyloid hypothesis, determine the timing of treatment, and lead the way to Alzheimer's disease prevention...
- High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trialPaul S Aisen
Department of Neurosciences, University of California, San Diego, 9500 Gilman Dr, M C 0949, La Jolla, CA 92093, USA
JAMA 300:1774-83. 2008..Prior studies of B vitamins to reduce homocysteine in AD have not had sufficient size or duration to assess their effect on cognitive decline...
- Clinical Core of the Alzheimer's Disease Neuroimaging Initiative: progress and plansPaul S Aisen
Department of Neurosciences, University of California San Diego, CA, USA
Alzheimers Dement 6:239-46. 2010..The resulting data would provide valuable data on the earliest stages of AD, and support the development of interventions in these critically important populations...
- Longitudinal change of biomarkers in cognitive declineRaymond Y Lo
Division of Epidemiology, University of California, Berkeley, 94720 3190, USA
Arch Neurol 68:1257-66. 2011....
- Mild cognitive impairment: baseline and longitudinal structural MR imaging measures improve predictive prognosisLinda K McEvoy
Department of Radiology, University of California, San Diego, 9500 Gilman Dr, La Jolla, CA 92093, USA
Radiology 259:834-43. 2011..To assess whether single-time-point and longitudinal volumetric magnetic resonance (MR) imaging measures provide predictive prognostic information in patients with amnestic mild cognitive impairment (MCI)...
- Influence of apolipoprotein E varepsilon4 on rates of cognitive and functional decline in mild cognitive impairmentDanielle C Whitehair
Department of Neurosciences, University of California, San Diego, CA, USA
Alzheimers Dement 6:412-9. 2010..We examine the prospective association of APOE varepsilon4 allele status on measures of cognitive and functional decline in subjects with amnestic MCI (aMCI)...
- Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measuresDouglas R Galasko
Department of Neurosciences, University of California, San Diego, 92093, USA
Arch Neurol 69:836-41. 2012..To evaluate whether antioxidant supplements presumed to target specific cellular compartments affected cerebrospinal fluid (CSF) biomarkers...
- Requiring an amyloid-beta1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trialsLon S Schneider
Department of Psychiatry, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
Alzheimers Dement 6:367-77. 2010....
- CSF biomarker and PIB-PET-derived beta-amyloid signature predicts metabolic, gray matter, and cognitive changes in nondemented subjectsMichael Ewers
Department of Radiology, University of California, San Francisco, 94143, USA
Cereb Cortex 22:1993-2004. 2012....
- 3D comparison of low, intermediate, and advanced hippocampal atrophy in MCILiana G Apostolova
Department of Neurology, David Geffen School of Medicine, UCLA, CA, USA
Hum Brain Mapp 31:786-97. 2010..Greater CA1 and subicular atrophy can be demonstrated early and is predictive of future conversion to AD, whereas CA2-3 involvement becomes more evident as the disease progresses...
- Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjectsE C Mormino
Helen Wills Neuroscience Institute, University of California, Berkeley, Berkeley, CA 94720, USA
Brain 132:1310-23. 2009..This pattern suggests that declining EM in older individuals may be caused by Abeta-induced hippocampus atrophy...
- Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trialsMichael Grundman
Alzheimer s Disease Cooperative Study, Department of Neurosciences, University of California San Diego, 8950 Villa La Jolla Drive, Suite 227, La Jolla, CA 92037, USA
Arch Neurol 61:59-66. 2004..The Memory Impairment Study (MIS) is a multicenter clinical trial in patients with MCI designed to evaluate whether vitamin E or donepezil is effective at delaying the time to a clinical diagnosis of AD...
- Neuroimaging enrichment strategy for secondary prevention trials in Alzheimer diseaseLinda K McEvoy
Department of Radiology, University of California, San Diego, La Jolla, CA 92093 0841, USA
Alzheimer Dis Assoc Disord 24:269-77. 2010..Failure to take into account normal age-related changes risks under-powering trials designed to test disease-modifying properties of potential treatments...
- NIA-funded Alzheimer centers are more efficient than commercial clinical recruitment sites for conducting secondary prevention trials of dementiaSteven D Edland
Department of Neurosciences, University of California San Diego, La Jolla, CA, USA
Alzheimer Dis Assoc Disord 24:159-64. 2010..Targeted retention efforts and utilization of academic sites could substantively improve the statistical power and validity of future clinical trials of cognitively impaired elderly...
- Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer diseaseAdam S Fleisher
University of California, San Diego, La Jolla, CA 92037, USA
Arch Neurol 65:1031-8. 2008..To evaluate the safety, tolerability, and amyloid beta (Abeta) response to the gamma-secretase inhibitor LY450139 in Alzheimer disease...
- MRI substudy participation in Alzheimer disease (AD) clinical trials: baseline comparability of a substudy sample to entire study populationRema Raman
Department of Neurosciences, University of California San Diego, La Jolla, 92093 0717, USA
Alzheimer Dis Assoc Disord 23:333-6. 2009..To determine if a self-selected group of participants who enroll in an imaging substudy of Alzheimer disease (AD) clinical trials is representative of the overall study sample...
- The Alzheimer's disease neuroimaging initiative: progress report and future plansMichael W Weiner
Center for Imaging of Neurodegenerative Diseases, San Francisco VA Medical Center, San Francisco, CA, USA
Alzheimers Dement 6:202-11.e7. 2010..All data are available at UCLA/LONI/ADNI, without embargo. ADNI-like projects started in Australia, Europe, Japan, and Korea. ADNI provides significant new information concerning the progression of AD...
- Subregional neuroanatomical change as a biomarker for Alzheimer's diseaseDominic Holland
Department of Neurosciences, University of California at San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA
Proc Natl Acad Sci U S A 106:20954-9. 2009..The findings indicate that regional temporal lobe cortical changes would have great utility as outcome measures in clinical trials and may also have utility in clinical practice for aiding early diagnosis of neurodegenerative disease...
- Identifying cognitively healthy elderly individuals with subsequent memory decline by using automated MR temporoparietal volumesGloria C Chiang
Department of Radiology, University of California, San Francisco, 505 Parnassus Ave, Room M391, San Francisco, CA, 94143, USA
Radiology 259:844-51. 2011..To determine whether automated temporoparietal brain volumes can be used to accurately predict future memory decline among a multicenter cohort of cognitively healthy elderly individuals...
- Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiativeOwen Carmichael
Department of Neurology, School of Medicine, University of California, Davis, CA, USA
Arch Neurol 67:1370-8. 2010....
- Dependence as a unifying construct in defining Alzheimer's disease severityTrent McLaughlin
Janssen Alzheimer Immunotherapy Research and Development, South San Francisco, CA, USA
Alzheimers Dement 6:482-93. 2010..This article presents the concept of dependence on others for care needs as a potential method for translating the effect of changes in cognition, function, and behavior into a more holistic, transparent description of AD progression...
- Effect of study partner on the conduct of Alzheimer disease clinical trialsJoshua D Grill
From the Mary Easton Center for Alzheimer s Disease Research J D G, Department of Neurology, University of California, Los Angeles Department of Family and Preventive Medicine R R, K E and Alzheimer s Disease Cooperative Study R R, K E, P A, University of California, San Diego and University of Pennsylvania J K, Perelman School of Medicine, Departments of Medicine, and Medical Ethics and Health Policy, Penn Memory Center, Philadelphia
Neurology 80:282-8. 2013..Alzheimer disease (AD) dementia clinical trials require 2 participants: a patient and a study partner. We assessed the prevalence of study partner types and how these types associate with patient-related outcome measures...
- Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humansTrygve E Bakken
Medical Scientist Training Program, University of California at San Diego, La Jolla, CA 92093, USA
Proc Natl Acad Sci U S A 109:3985-90. 2012..We suggest that identifying genes that contribute to normal cortical architecture provides a first step to understanding genetic mechanisms that underlie visual perception...
- Voxelwise genome-wide association study (vGWAS)Jason L Stein
Laboratory of Neuro Imaging, Department of Neurology, University of California, Los Angeles School of Medicine, Neuroscience Research Building 225E, 635 Charles Young Drive, Los Angeles, CA 90095 1769, USA
Neuroimage 53:1160-74. 2010..These genes have high relevance to brain structure. This is the first voxelwise genome wide association study to our knowledge, and offers a novel method to discover genetic influences on brain structure...
- Applications of neuroimaging to disease-modification trials in Alzheimer's diseaseAdam S Fleisher
Department of Neurosciences, University of California, San Diego, USA
Behav Neurol 21:129-36. 2009..This review discusses recently presented data from the ADNI dataset, and the importance of imaging in the future of drug development in AD...
- Leon Thal and the therapeutic age of Alzheimer's diseasePaul S Aisen
University of California San Diego, San Diego, CA, USA
Alzheimers Dement 4:S4-6. 2008
- Pilot Study of Huperzine A in Alzheimer's DiseasePaul Aisen; Fiscal Year: 2003....
- A Phase 2 Trial of AAV-NGF Gene Delivery in Alzheimer's DiseasePaul Aisen; Fiscal Year: 2009..Alzheimer's disease is among the most important health problems worldwide, with steadily rising prevalence as populations age. Effective disease-modifying treatment is sorely needed. ..
- A Phase 2 Trial of AAV-NGF Gene Delivery in Alzheimer's DiseasePaul S Aisen; Fiscal Year: 2010..Alzheimer's disease is among the most important health problems worldwide, with steadily rising prevalence as populations age. Effective disease-modifying treatment is sorely needed. ..